AescapInvesting in Medicine
Aescap Life Sciences is a biotech fund that invests in publicly traded biotech companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and/or medical devices. Aescap Life Sciences has around 185 million euros under management and has an annualized net performance of 14% since inception over five years ago. Entry into and exit from this biotech fund is possible twice per month.
Performance
Our net performance, since inception on March 28th 2016, is +103%, representing an annualized net IRR of around 14%, which is 31% above the return of the Nasdaq Biotech Index.
Get in touch
Our monthly presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on August 18th at 15.00 cet.
Newsletter
Want to stay up to date?
Just subscribe to our newsletter here
Strategy
Aescap Life Sciences has a focused portfolio, investing in around 18 public biotech / life science companies. Most of the companies in our portfolio are based in Europe and the US. Our investment decisions are based on ‘high conviction’, fueled by thorough research and fundamental analyses. In the biotech sector such an analysis especially encompasses product portfolio patent protection, product development risks, market entry barriers, competition and the expected market development. But equally important are the serious efforts we undertake to understand the strengths and weakness of a company’s management, team dynamics, and their view on the future of the company and the markets they serve.
PATRICK KROL, PORTFOLIO MANAGER
Patrick joined Aescap at its start in 2005 when it was active as a biotech venture capital fund. Patrick has been a private investor in public equity for over 30 years. Building on his track record as a private investor in public biotech companies , outperforming the Nasdaq Biotech Index over 2,5x, he founded Aescap Life Sciences early 2016. As a co-founder of Firm United Healthcare he was responsible for growing the company into a market leader on the European continent and guided over 35 listed pharma and biotech companies to successfully introduce or grow their products.
5-star rating
Morningstar has rated Aescap Life Sciences as a 5-star investment fund, the highest possible rating given. Morningstar’s rating has become the industry’s leading standard for determining a fund’s performance (risk/reward) relative to other funds. To rate a fund, Morningstar takes into account the long-term performance (3+ years) and only the top 10% best performing funds will receive a 5-star rating.
See Aescap on Morningstar
Latest News
Aescap Life Sciences Quarterly Update Q1 2021
Our portfolio companies delivered a series of value creating events, such as improved financials, approval of new products, profitable licensing deals and superior clinical study data. Despite these positive developments during Q1, our NAV ended the quarter at -3% due to stock markets being unfavorable for the biotech sector as a whole.
Aescap 2.0 becomes Aescap Life Sciences
After operating under the name Aescap 2.0 for almost 5 years, we feel our new name better represents our investment focus and the impact our companies have on the life of patients in need.